Carcinoembryonic antigen (CEACAM5, also known as CEA or CD66e), belongs to the large CEACMA subfamily in the immunoglobulin superfamily. CEA is mainly expressed by epithelial cells and is a glycoprotein with a molecular weight of 180kDa and 60% carbohydrates. There is an immunoglobulin V-type domain at the N-terminus of CEA , followed by 6 immunoglobulin C2-type domains and a glycosylphosphatidylinositol anchor (also called insertio), so the same Exist in the form of source dimer. CEACAM5 and CEACAM6 are overexpressed in many tumor tissues, and they are related to tissue adhesion and invasion. It functions as an adhesion molecule between cells of the same type and is a widely used tumor marker. Compared with normal tissues, it has a higher expression level in tumor tissues. This product is a second-generation CAR lentiviral expression vector targeting CEA, which can be used for in vivo and in vitro pharmacodynamic experiments.

Product name: Lenti-EF1a-CEA-2nd-CAR-puro

Promoter: EF1a [1]

Co-activation of intracellular signaling: 4-1BB / CD3Zata

Resistance gene: Amp



 Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.